Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Radiopharm Theranostics Limited ( (AU:RAD) ) has provided an announcement.
Radiopharm Theranostics Limited announced a proposed issue of 30,969,360 ordinary fully paid securities, with the issuance date set for June 13, 2025. This move is part of a strategic placement to potentially enhance the company’s capital structure, which could strengthen its market position and provide additional resources for its ongoing projects in the radiopharmaceutical sector.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the healthcare industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is committed to advancing innovative solutions in the field of nuclear medicine, aiming to enhance patient outcomes through targeted radiotherapy and imaging technologies.
Average Trading Volume: 4,436,932
Technical Sentiment Signal: Sell
Current Market Cap: A$58.35M
See more data about RAD stock on TipRanks’ Stock Analysis page.